- ASSOCIATE PROFESSOR | Medicine, Nephrology
- Internal Medicine
- Hospital Affiliation
- The Mount Sinai Hospital
- Department of Medicine-Renal Medicine 212-241-4060212-241-4060
American Board of Internal Medicine
- Acute Renal Failure
- Chronic Renal Failure
- High Blood Pressure
- Kidney Biopsy
- Nephrotic Syndrome
MD, Albany Medical College
Residency, Internal Medicine
Mount Sinai Hospital
Mount Sinai Hospital
The contribution of dyslipidemia to cardiovascular disease in the renal disease population
The most common cause for mortality in the end-stage renal disease patients is cardiovascular disease. My previous research investigated the putative roles of molecular chaperones in apolipoprotein B metabolism, the primary protein moiety of the LDL and VLDL lipoproteins. Among the molecules studied were gp78, cdc97, microsomal triglyceride transfer protein and their respective mechanisms at the cellular and molecular levels.
Currently the goal is to integrate this basic science with patient care and to develop a clinical trial.
Wei G, Lonardo F, Ueda T, Kim T, Huvos AG, Healy JH, Ladanyi M. CDK4 Gene Amplification in Osteosarcoma: Reciprocal Relationship in INK 4A Gene Alterations and Mapping of 12q13 Amplicons. International Journal of Cancer 1999; 80: 199-204.
Jones S, Kim T. Fulminant Leptospirosis in a Patient with Human Immunodeficiency Virus Infection: Case Report and Review of Literature. Clinical Infectious Diseases 2001 Sep 1; 33(5): E31-33.
Liang J, Kim T, Fang S, Yamaguchi J, Weissman A, Fisher E, Ginsberg H. Overexpression of theTumor Autocrine Motility Factor Receptor gp78, a Ubiquitin Protein Ligase, Results in Increased Ubiquitylation and Decreased Secretion of Apolipoprotein B100 in HepG2 Cells. J Biol Chem 2003; 278(26): 23984-23988.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Kim did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.